Gastrointestinal tract anatomy alteration

Gastrointestinal tract anatomy alteration" refers to **structural changes made to the normal anatomical configuration of the gastrointestinal (GI) tract**. These alterations are most commonly performed surgically for therapeutic reasons—such as bariatric surgery for weight loss or resection for cancer or inflammatory disease—or may result from congenital anomalies or trauma[3]. Examples include gastric bypass surgery (which changes stomach size and reroutes intestines), partial gastrectomy, bowel resections, and stoma creation. Such alterations are not molecular targets like receptors, enzymes, transporters, or other biomolecules. Instead, they describe a physical change at the organ/tissue level. While these changes can profoundly affect digestion and absorption—impacting nutrient uptake and sometimes drug pharmacokinetics—they do not represent a single molecule or protein that can be targeted by drugs[3][6]. Because "Gastrointestinal tract anatomy alteration" is an anatomical/surgical concept rather than a discrete molecular entity: - It is **not considered a therapeutic target** in the conventional sense used in pharmacology. - There is no canonical abbreviation. - There are no direct interacting drugs; however, patients with altered GI anatomy may require special consideration regarding medication choice/dosing due to changed absorption profiles. - No specific biomarkers exist for this "target," though nutritional markers may be monitored post-surgery. In summary: This entry does **not correspond to a valid molecular target** but rather describes an anatomical state resulting from medical intervention or disease. If you seek information on specific molecules involved in GI function (e.g., receptors affected by such surgeries), please specify further[3][6].

Other names

Altered gastrointestinal anatomyGI tract anatomical modificationGastrointestinal surgical alteration